Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma

The efflux transporter breast cancer resistance protein BCRP/ABCG2 is well‐known for its contribution to multi‐drug resistance in cancer. Its relevance in cancer biology independent from drug efflux remains largely elusive. Our study aimed at elucidating the biological relevance and regulatory mechanisms of BCRP/ABCG2 in clear cell renal cell carcinoma (ccRCC) and disease progression. Two independent ccRCC‐cohorts [Cohort 1 (KIRC/TCGA): n = 453, Cohort 2: n = 64] were investigated to elucidate BCRP/ABCG2 mRNA and protein expression and their association with survival. The impact of BCRP/ABCG2 on response to sunitinib treatment was investigated in two independent sunitinib‐treated ccRCC‐cohorts based on mRNA levels. Moreover, underlying regulatory mechanisms for interindividual variability of BCRP/ABCG2 expression were systematically assessed. Owing to redundant functional properties, mRNA and protein expression of the multidrug resistance protein MDR1/ABCB1 were additionally evaluated in these cohorts. In independent ccRCC‐cohorts, low BCRP/ABCG2 and MDR1/ABCB1 mRNA and protein expression were associated with severity (e.g., tumor stage) of ccRCC and poor cancer‐specific survival. BCRP/ABCG2 and MDR1/ABCB1 mRNA expression were linked to decreased progression‐free survival after sunitinib treatment. Germline and somatic variants influenced interindividual variability of BCRP/ABCG2 expression only moderately. miR‐212‐3p and miR‐132‐3p were identified to regulate BCRP/ABCG2 posttranscriptionally by interaction with the ABCG2 3′UTR as confirmed through reporter gene assays in RCC cell lines. In summary, BCRP/ABCG2 expression in ccRCC underlies considerable interindividual variability with impact on patient survival and response to sunitinib treatment. While germline or somatic genetic variants and DNA methylation cannot explain aberrant BCRP/ABCG2 expression, miR‐212‐3p and miR‐132‐3p were identified to contribute to posttranscriptional regulation of BCRP/ABCG2.

[1]  M. Gottesman,et al.  Revisiting the role of ABC transporters in multidrug-resistant cancer , 2018, Nature Reviews Cancer.

[2]  R. Weiss,et al.  ONCONEPHROLOGY: Metabolic reprogramming in clear cell renal cell carcinoma , 2017 .

[3]  K. Bensalah,et al.  European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma , 2016 .

[4]  S. Ng,et al.  A novel miR‐203‐DNMT3b‐ABCG2 regulatory pathway predisposing colorectal cancer development , 2017, Molecular carcinogenesis.

[5]  S. Laufer,et al.  Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. , 2016, Trends in pharmacological sciences.

[6]  U. Hofmann,et al.  Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes , 2016, Scientific Reports.

[7]  Lixia Lv,et al.  Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells. , 2016, Oncology letters.

[8]  Arndt Hartmann,et al.  Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. , 2015, European urology.

[9]  M. Schwab,et al.  MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma , 2015, Oncotarget.

[10]  B. Rini,et al.  CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. , 2015, European urology.

[11]  N. Rioux-Leclercq,et al.  Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting , 2015, Clinical Cancer Research.

[12]  L. Huo,et al.  Synthetic miR-145 Mimic Enhances the Cytotoxic Effect of the Antiangiogenic Drug Sunitinib in Glioblastoma , 2015, Cell Biochemistry and Biophysics.

[13]  H. Yoshiji,et al.  Differential Expression of Drug Uptake and Efflux Transporters in Japanese Patients with Hepatocellular Carcinoma , 2014, Drug Metabolism and Disposition.

[14]  I. Cascorbi,et al.  Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance , 2014, Expert opinion on drug metabolism & toxicology.

[15]  I. Cascorbi,et al.  MicroRNAs and their relevance to ABC transporters. , 2014, British journal of clinical pharmacology.

[16]  D. Rosskopf,et al.  Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme , 2013, BMC Cancer.

[17]  M. Schwab,et al.  DNA Methylation of the SLC16A3 Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome , 2013, Clinical Cancer Research.

[18]  Lin Zhao,et al.  MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2) , 2013, Breast Cancer Research and Treatment.

[19]  J. Patard,et al.  Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib , 2013, British Journal of Cancer.

[20]  J. Engel,et al.  Human Pregnane X Receptor Genotype of the Donor but Not of the Recipient Is a Risk Factor for Delayed Graft Function After Renal Transplantation , 2012, Clinical pharmacology and therapeutics.

[21]  D. Ross,et al.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. , 2012, Biochemical pharmacology.

[22]  I. Cascorbi,et al.  MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression , 2012, Pharmacogenetics and genomics.

[23]  J. Schuetz,et al.  The role of ABCG2 and ABCB6 in porphyrin metabolism and cell survival. , 2011, Current pharmaceutical biotechnology.

[24]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[25]  H. Guchelaar,et al.  Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib , 2010, Clinical Cancer Research.

[26]  J. Fletcher,et al.  ABC transporters in cancer: more than just drug efflux pumps , 2010, Nature Reviews Cancer.

[27]  Y. Assaraf,et al.  Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. , 2009, Neoplasia.

[28]  Feng Bing,et al.  Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1) , 2009, Journal of cellular and molecular medicine.

[29]  Thomas Ried,et al.  Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2 , 2009, Molecular Cancer Therapeutics.

[30]  E. Boerwinkle,et al.  Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout , 2009, Proceedings of the National Academy of Sciences.

[31]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[32]  S. Bates,et al.  ABCG2: a perspective. , 2009, Advanced drug delivery reviews.

[33]  F. Russel,et al.  The Role of ATP Binding Cassette Transporters in Tissue Defense and Organ Regeneration , 2009, Journal of Pharmacology and Experimental Therapeutics.

[34]  F. Russel,et al.  The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. , 2008, Kidney international.

[35]  M. Schell,et al.  ABCG2 expression, function, and promoter methylation in human multiple myeloma. , 2006, Blood.

[36]  S. Bates,et al.  Aberrant Promoter Methylation of the ABCG2 Gene in Renal Carcinoma , 2006, Molecular and Cellular Biology.

[37]  R. Martindale,et al.  Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. , 2006, Biochemical and biophysical research communications.

[38]  I. Catalá,et al.  Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material , 2002, The Journal of pathology.

[39]  U. Brinkmann,et al.  Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. , 2002, Journal of the American Society of Nephrology : JASN.

[40]  A. Wittmann,et al.  Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer? , 1997, British journal of urology.

[41]  I. Andrulis,et al.  Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  I. Pastan,et al.  MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. , 1989, Journal of the National Cancer Institute.

[43]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[44]  Xin Li,et al.  Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. , 2011, Biochemical pharmacology.

[45]  S. Donnini,et al.  Role of nitric oxide in tumor angiogenesis. , 2004, Cancer treatment and research.

[46]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .